UMIN-CTR Clinical Trial
BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials
Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000024074
Receipt No. R000027697
Scientific Title Gluten sensitivity among the patients with schizophrenia and the possibility of therapeutic effect of gluten free diet
Date of disclosure of the study information 2016/10/04
Last modified on 2019/03/22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title Gluten sensitivity among the patients with schizophrenia and the possibility of therapeutic effect of gluten free diet
Acronym Gluten sensitivity and therapeutic effect of gluten free diet for schizophrenia
Scientific Title Gluten sensitivity among the patients with schizophrenia and the possibility of therapeutic effect of gluten free diet
Scientific Title:Acronym Gluten sensitivity and therapeutic effect of gluten free diet for schizophrenia
Region
Japan

Condition
Condition schizophrenia
Classification by specialty
Psychiatry
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To clarify the gluten sensitivity and its relationships between symptoms , severity, and drugs responsibility among the patients with schizophrenia in Japan and effectiveness of gluten free diet for the schizophrenia patients with gluten sensitivity.
Basic objectives2 Others
Basic objectives -Others To measure the antibody related to gluten sensitivity with the plasma obtained from the patients with schizophrenia.
To investigate the effectiveness of gluten free diet for the schizophrenia patients with gluten sensitivity, open trail with gluten free diet for two weeks is performed
Trial characteristics_1 Confirmatory
Trial characteristics_2 Others
Developmental phase Not applicable

Assessment
Primary outcomes Assessment of gluten sensitivity is determined by the titer of tissue transglutaminase IgA antibody, the deamidated gliadin peptide IgA antibody, gliadin IgA antibody, gliadin IgGa nti body.
The effectiveness of gluten free diet is assessed by PANSS before and two weeks later of taking gluten free diet. Improved patients is assessed at four and eight weeks.
Key secondary outcomes The comparison between gluten sensitivity group and gluten negative group is performed by PANSS, GAF, SOFAS, QOL-26.
The effectiveness of gluten free diet is assessed by CGI-I

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification NO
Dynamic allocation NO
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 gluten sensitive patients with schizophrenia have gluten free diet for two weeks. Patients whose symptoms are improved (PANSS score decrease twenty percents or CGI-I score above three at two weeks) continue gluten free diet for eight weeks.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
70 years-old >=
Gender Male and Female
Key inclusion criteria patient who met the criteria of schizophrenia in the DSM-5
patient who can understand the purpose of this study and be approved to participate by doctor
patient who can provide written informed consent
Key exclusion criteria patient with remarkable excitement, violent action, self-injurious behavior
patient with social behavior
patinet who can't provide written informed consent
patient who have substance abuse or dependent
Target sample size 280

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yamada Hisashi
Organization hyogo medical college
Division name department of psychiatry
Zip code
Address 1-1, mukogawatyo, nisinomiya city, hyogo
TEL 0798-45-6051
Email hisa0820@hyo-med.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name yamada hisashi
Organization hyogo medical college
Division name department of psychiatry
Zip code
Address 1-1, mukogawatyo, nisinomiya city, hyogo
TEL 0798-45-6051
Homepage URL
Email hisa0820@hyo-med.ac.jp

Sponsor
Institute hyogo medical college
department of psychiatry
Institute
Department

Funding Source
Organization Hyogo College of Medicine
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor Mihara hospital
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 10 Month 04 Day

Related information
URL releasing protocol
Publication of results Partially published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results 
There was no significant difference in gluten sensitivity between groups schizophrenia and controls. AG-IgG plasma concentration was significantly higher in patients with schizophrenia than in controls. Treatment-resistant patients in gluten sensitivity were significantly much more than those in non-gluten sensitivity. We found that AG-IgG concentration in treatment-resistant patients is significantly higher than that in non-treatment-resistant patients.
Results date posted
2019 Year 03 Month 22 Day
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2016 Year 10 Month 04 Day
Date of IRB
2016 Year 10 Month 04 Day
Anticipated trial start date
2016 Year 10 Month 04 Day
Last follow-up date
2025 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 09 Month 15 Day
Last modified on
2019 Year 03 Month 22 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027697

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name

Contact us.